AI Article Synopsis
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the main treatment for advanced non-small cell lung cancer (NSCLC) patients with specific EGFR mutations, but resistance to these drugs often develops.
- Research is focusing on understanding the mechanisms behind this drug resistance and finding alternative treatment options.
- Immune checkpoint inhibitors (ICIs) are emerging as a new treatment option for late-stage NSCLC patients who have developed resistance to EGFR-TKIs, with studies investigating their effectiveness alone or in combination with other therapies.
Article Abstract
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment choice for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. EGFR-TKIs have made significant progress in the treatment of advanced NSCLC patients, but drug resistance issues still inevitably arise. The mechanism of drug resistance and subsequent treatment has been current research challenge and priority. Immune checkpoint inhibitors (ICIs) are a new choice for late-stage NSCLC patients without druggable molecular alterations. Currently, several studies have applied ICIs therapy for NSCLC patients with EGFR-TKIs resistance and explored the potential efficacy of ICIs. This review elaborates on the current status of immunotherapy after EGFR-TKIs resistance, including ICIs monotherapy, combined with EGFR-TKIs, chemotherapy, antiangiogenic drugs, and other therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617040 | PMC |
| http://dx.doi.org/10.1111/crj.70037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!